List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8096451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Histopathological characteristics of central nervous system in chronic progressive neuro-Behçet's disease. Journal of the Neurological Sciences, 2022, 434, 120127.	0.3	0
2	Enhanced expression of mRNA for transforming growth factor \hat{I}^2 activated kinase 1 in CD34+ cells of the bone marrow in rheumatoid arthritis Clinical and Experimental Rheumatology, 2022, , .	0.4	0
3	Role of Serum ILâ€6 in Neuropsychiatric Systemic lupus Erythematosus. ACR Open Rheumatology, 2021, 3, 42-49.	0.9	20
4	Antiâ€ f ibosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia. International Journal of Rheumatic Diseases, 2021, 25, 70.	0.9	0
5	Histopathology of perforated gastrointestinal tracts in Behçet's disease: evidence for the critical role of thrombophilia. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 137-138.	0.4	0
6	Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease. Internal Medicine, 2020, 59, 2359-2367.	0.3	11
7	Anti-ribosomal P protein antibodies influence mortality of patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematous involving a severe form of the disease. Modern Rheumatology, 2019, 29, 612-618.	0.9	15
8	Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus. Lupus Science and Medicine, 2019, 6, e000359.	1.1	9
9	Imaging of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 113-127.		0
10	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. Arthritis and Rheumatology, 2018, 70, 277-286.	2.9	45
11	Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes. Modern Rheumatology, 2018, 28, 506-512.	0.9	3
12	Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000281.	1.1	15
13	Synergistic enhancement of production of proinflammatory cytokines of human peripheral blood monocytes by anti-Sm and anti-RNP antibodies. PLoS ONE, 2018, 13, e0209282.	1.1	7
14	Immunopathology of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 29-42.		1
15	Epidemiology of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 1-13.		1
16	Pathology of Neuropsychiatric Systemic Lupus Erythematosus. , 2018, , 43-58.		1
17	Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2018, 36, 1003-1007.	0.4	20
18	Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus. Modern Rheumatology, 2017, 27, 292-297.	0.9	18

#	Article	IF	CITATIONS
19	Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Modern Rheumatology, 2017, 27, 278-283.	0.9	19
20	Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis. Scientific Reports, 2017, 7, 10196.	1.6	26
21	Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis. Modern Rheumatology, 2017, 27, 766-772.	0.9	16
22	Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. PLoS ONE, 2017, 12, e0186414.	1.1	34
23	Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease. Medicine (United States), 2016, 95, e3863.	0.4	77
24	Transverse myelitis extended to disseminated encephalitis in systemic lupus erythematosus: Histological evidence for vasculitis. Modern Rheumatology, 2016, 26, 958-962.	0.9	12
25	Association of antibodies to the NR1 subunit of <i>N</i> -methyl- <i>D</i> -aspartate receptors with neuropsychiatric systemic lupus erythematosus. Modern Rheumatology, 2016, 26, 377-383.	0.9	22
26	Effects of anti-IL-6 receptor antibody on human monocytes. Modern Rheumatology, 2015, 25, 79-84.	0.9	12
27	Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. Journal of the Neurological Sciences, 2015, 349, 143-148.	0.3	32
28	Increased generation of pre-plasmacytoid dendritic cells in bone marrow of rheumatoid arthritis. Modern Rheumatology, 2014, 24, 443-447.	0.9	7
29	Analysis of various factors on the relapse of acute neurological attacks in Behçet's disease. Modern Rheumatology, 2014, 24, 961-965.	0.9	8
30	Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Lupus Science and Medicine, 2014, 1, e000050.	1.1	27
31	Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Research and Therapy, 2014, 16, R77.	1.6	82
32	Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Research and Therapy, 2014, 16, 450.	1.6	49
33	Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Beh§et's disease. Journal of the Neurological Sciences, 2014, 337, 80-85.	0.3	23
34	Efficacy of anti-ribosomal P protein antibody testing for diagnosis of systemic lupus erythematosus. Modern Rheumatology, 2014, 24, 939-944.	0.9	13
35	TNF inhibitors induce discoid fibrosis in the sublining layers of the synovium with degeneration of synoviocytes in rheumatoid arthritis. Rheumatology International, 2013, 33, 2473-2481.	1.5	11
36	lgG anti–NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis and Rheumatism, 2013, 65, 457-463.	6.7	89

#	Article	IF	CITATIONS
37	Role of FK506 binding protein 5 (FKBP5) in osteoclast differentiation. Modern Rheumatology, 2013, 23, 1133-1139.	0.9	9
38	Role of FK506 binding protein 5 (FKBP5) in osteoclast differentiation. Modern Rheumatology, 2013, 23, 1133-9.	0.9	6
39	Changes in Biomarkers Focused on Differences in Disease Course or Treatment in Patients with Neuro-Behçet's Disease. Internal Medicine, 2012, 51, 3359-3365.	0.3	39
40	Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Modern Rheumatology, 2012, 22, 405-413.	0.9	73
41	Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Modern Rheumatology, 2012, 22, 405-413.	0.9	48
42	Induction of type B synoviocyte-like cells from plasmacytoid dendritic cells of the bone marrow in rheumatoid arthritis and osteoarthritis. Clinical Immunology, 2011, 140, 276-283.	1.4	13
43	Anti-ribosomal P antibodies and lupus nephritis. Clinical and Experimental Nephrology, 2011, 15, 471-477.	0.7	19
44	Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Modern Rheumatology, 2011, 21, 57-62.	0.9	17
45	Histopathological analysis of cerebral hemorrhage in systemic lupus erythematosus complicated with antiphospholipid syndrome. Modern Rheumatology, 2011, 21, 509-513.	0.9	8
46	Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Modern Rheumatology, 2011, 21, 57-62.	0.9	11
47	Histopathological analysis of cerebral hemorrhage in systemic lupus erythematosus complicated with antiphospholipid syndrome. Modern Rheumatology, 2011, 21, 509-513.	0.9	4
48	Neuromuscular Involvement in Connective Tissue Diseases The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1751-1753.	0.0	0
49	1. Serological Markers of Neuropsychiatric Disorders in Patients with Collagen Vascular Diseases The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1858-1864.	0.0	0
50	Suppressive influences of IFN-α on IL-17 expression in human CD4+ T cells. Clinical Immunology, 2010, 134, 340-344.	1.4	11
51	An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. Modern Rheumatology, 2010, 20, 621-626.	0.9	21
52	Behçet's Syndrome and the Nervous System. , 2010, , 95-113.		6
53	An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. Modern Rheumatology, 2010, 20, 621-626.	0.9	12
54	Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clinical Rheumatology, 2009, 28, 1319-1323.	1.0	104

#	Article	IF	CITATIONS
55	Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients. International Immunopharmacology, 2009, 9, 86-90.	1.7	16
56	Association of cerebrospinal fluid anti–NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 58, 1130-1135.	6.7	213
57	Histopathology of central nervous system lesions in Behçet's disease. Journal of the Neurological Sciences, 2008, 267, 41-47.	0.3	121
58	Reversible focal neurological deficits in systemic lupus erythematosus: Report of 2 cases and review of the literature. Journal of the Neurological Sciences, 2008, 272, 71-76.	0.3	15
59	Effect of infliximab in progressive Neuro-Behçet's syndrome. Journal of the Neurological Sciences, 2008, 272, 99-105.	0.3	107
60	HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behçet's disease. Modern Rheumatology, 2007, 17, 81-82.	0.9	42
61	Potential New Therapeutic Options for Involvement of Central Nervous System in Behcets Disease (Neuro-Behcets Syndrome). Current Rheumatology Reviews, 2007, 3, 297-303.	0.4	17
62	Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Research and Therapy, 2007, 9, R44.	1.6	68
63	HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behçet's disease. Modern Rheumatology, 2007, 17, 81-82.	0.9	26
64	Enhanced expression of mRNA for nuclear factor kappaB1 (p50) in CD34+ cells of the bone marrow in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R54.	1.6	15
65	Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. Arthritis and Rheumatism, 2006, 54, 312-324.	6.7	201
66	Role of Bone Marrow in the Pathogenesis of Rheumatoid Arthritis. Current Rheumatology Reviews, 2006, 2, 47-54.	0.4	1
67	Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis and Rheumatism, 2005, 52, 847-855.	6.7	61
68	Differential effects of IFN-α on the expression of various TH2 cytokines in human CD4+ T cells. Journal of Allergy and Clinical Immunology, 2005, 116, 205-212.	1.5	33
69	Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: Possible role in synovial neovascularization. Arthritis and Rheumatism, 2004, 50, 3888-3896.	6.7	32
70	Behçet's disease. Arthritis Research, 2003, 5, 139.	2.0	108
71	Cerebrospinal fluid β2-microglobulin in neuro-Behçet's syndrome. Journal of the Neurological Sciences, 2000, 179, 132-139.	0.3	24
72	Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 2729-2730.	6.7	30

#	Article	IF	CITATIONS
73	Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet, The, 1999, 353, 1331.	6.3	42
74	Suppressive Influences of Methotrexate on the Generation of CD14 (+) Monocyte-Lineage Cells from Bone Marrow of Patients with Rheumatoid Arthritis. Clinical Immunology, 1999, 91, 84-89.	1.4	6
75	Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis and Rheumatism, 1998, 41, 1819-1827.	6.7	129
76	Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. Journal of the Neurological Sciences, 1998, 159, 181-185.	0.3	120
77	Cerebrospinal Fluid Interleukin-6 in Progressive Neuro-Behçet's Syndrome. Clinical Immunology and Immunopathology, 1997, 82, 12-17.	2.1	114
78	Differential Influences of Gold Sodium Thiomalate and Bucillamine on the Generation of CD14 + Monocyte-Lineage Cells from Bone Marrow of Rheumatoid Arthritis Patients. Clinical Immunology and Immunopathology, 1997, 84, 290-295.	2.1	9
79	Interaction of indometacin farnesil, a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis Japanese Journal of Clinical Immunology, 1996, 19, 136-144.	0.0	2
80	Accelerated generation of CD14+ monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients. Arthritis and Rheumatism, 1996, 39, 836-843.	6.7	49
81	Association of anti–ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 1483-1490.	6.7	147
82	Comparative inhibitory effects of bucillamine and d-penicillamine on the function of human b cells and t cells. Arthritis and Rheumatism, 1994, 37, 942-950.	6.7	34
83	Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. Lancet, The, 1994, 343, 796.	6.3	24
84	Aseptic Necrosis of Unilateral Scaphoid Bone in Systemic Lupus Erythematosus Internal Medicine, 1992, 31, 794-797.	0.3	8
85	Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug. Arthritis and Rheumatism, 1992, 35, 168-175.	6.7	7
86	Quantitative determination of .ALPHA.2-macroglobulin in cerebrospinal fluids from various neurological diseases by enzymeimmunoassay Japanese Journal of Clinical Immunology, 1992, 15, 45-50.	0.0	1
87	Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system invol vement. Arthritis and Rheumatism, 1990, 33, 644-649.	6.7	276
88	Intravenous cyclophosphamide pulse therapy in idiopathic interstitial pneumonia: Report of a case Japanese Journal of Clinical Immunology, 1989, 12, 663-667.	0.0	0
89	Association of cerebrospinal fluid IgM index with central nervous system involvement in Behçet's disease. Arthritis and Rheumatism, 1986, 29, 793-796.	6.7	11
90	Cerebrospinal Fluid IgM, IgA, and IgG Indexes in Systemic Lupus Erythematosus. Archives of Internal Medicine, 1985, 145, 1843.	4.3	52

#	Article	IF	CITATIONS
91	A sensitive and simple method for determination of IgM in cerebrospinal fluid by a solid-phase enzyme-immunoassay. Journal of the Neurological Sciences, 1985, 67, 115-118.	0.3	23
92	Quantitation of IgC, IgA and IgM in the cerebrospinal fluid by a solid-phase enzyme-immunoassay. Journal of the Neurological Sciences, 1984, 63, 101-110.	0.3	17
93	A CASE OF A 49-YEAR-OLD MAN WITH POLYSPLENIA SYNDROME COMPLICATED BY GRAWITZ'S TUMOR OF KIDNEY. The Journal of the Japanese Society of Internal Medicine, 1982, 71, 502-506.	0.0	0